NCT05448001View on ClinicalTrials.gov

Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 in Patients With Gastric Ulcer

PHASE3CompletedINTERVENTIONAL
Enrollment

329

Participants

Timeline

Start Date

September 19, 2022

Primary Completion Date

July 10, 2024

Study Completion Date

July 19, 2024

Conditions
Gastric Ulcer
Interventions
DRUG

JP-1366 20mg

JP-1366 20 mg 1 capsule, Lansoprazole 30 mg placebo 1 capsule before meal

DRUG

Lansoprazole 30mg

JP-1366 20 mg placebo 1 capsule, Lansoprazole 30 mg 1 capsule before meal

Trial Locations (1)

Unknown

Korea University Kuro Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Onconic Therapeutics Inc.

INDUSTRY

NCT05448001 - Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 in Patients With Gastric Ulcer | Biotech Hunter | Biotech Hunter